Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 111814
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111814
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111814
Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib
Jia-Hui Yu, Jun Yu, Lin-Feng Yang, Duan Yan, Yi Liu, Peng-Sheng Yi, Department of Hepato-Pancreato-Biliary II, National Clinical Key Specialty, Sub-center of National Clinical Research Center for Digestive Diseases, Sichuan Clinical Research Center for Digestive Diseases, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
Jin-Xin Yu, Ju-Rui Xian, Department of Clinical Medicine, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
Author contributions: Yu JH and Yu J contributed to collect data; Yu JH and Yang LF contributed to data interpretation; Yu JH and Yi PS drafted and revised the manuscript; Yu JX and Liu Y contributed to the conception and design of the study; Yuan D and Xian JR contributed to statistical analyses; Yu JH and Yu J contributed equally to this manuscript and are co-first authors. All the authors have read and approved the final version of the manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the Affiliated Hospital of North Sichuan Medical College (Approval No. 2025ER258-1).
Informed consent statement: Informed consent has been waived for this article.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Peng-Sheng Yi, PhD, Department of Hepato-Pancreato-Biliary II, National Clinical Key Specialty, Sub-center of National Clinical Research Center for Digestive Diseases, Sichuan Clinical Research Center for Digestive Diseases, Affiliated Hospital of North Sichuan Medical College, No. 1 Maoyuan South Road, Nanchong 637000, Sichuan Province, China. 13065256256@163.com
Received: July 10, 2025
Revised: September 13, 2025
Accepted: October 21, 2025
Published online: November 15, 2025
Processing time: 127 Days and 11.9 Hours
Revised: September 13, 2025
Accepted: October 21, 2025
Published online: November 15, 2025
Processing time: 127 Days and 11.9 Hours
Core Tip
Core Tip: We summarized risk factors (number of tumors, microvascular invasion, Eastern Cooperative Oncology Group performance status, Child-Pugh stage, etc.) and protective factor (triple therapy) for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib, constructed and validated prognostic models. In the validation set, area under the curve values of overall survival and progression-free survival, calibration curves, etc., con